Intensive Insulin Therapy Saves Lives– But Is The Finding Still Relevant? 1

A trial that started back in 1990 continues to demonstrate a significant mortality advantage for intensive insulin therapy in heart attack (MI) patients. But experts say the trial design is so outdated that the findings should have no influence on clinical practice today.

During the years 1990 through 1993 the Swedish DIGAMI I (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infaction 1) trial randomized 620 MI patients with elevated glucose levels to either intensive insulin treatment or conventional therapy. Earlier results from the trial showed beneficial effects, including improved survival, for patients in the intensive treatment arm.

Now, a paper published in The Lancet Diabetes & Endocrinology, presents 20-year followup results showing an average 2.3 year increase in survival for patients in the treatment arm (median survival 7.0 years versus 4.7 years, HR 0.83, CI 0.70-0.98, p=0.27).

Click here to read the entire post on Forbes, including an extensive comment from Darren McGuire.

 

About these ads

Seeking Cardiovascular Safety Data, FDA Blocks Approval Of Novo Nordisk’s Long-Acting Insulin Reply

The FDA informed Novo Nordisk on Friday that it would not approve the company’s highly anticipated long-acting insulin degludec products (Tresiba and Ryzodeg) until it receives data from a cardiovascular outcomes trial. Approval of the drugs had been widely anticipated for this year, following a positive recommendation from an FDA advisory committee last fall. But the committee also unanimously recommended that the company be required to perform a cardiovascular outcomes trial.

Click here to read the complete article on Forbes.

 

 

 

Guest Post– Reality Check: The ORIGIN of Spin in a Randomized Trial 2

Editor’s Note: The following guest post is reprinted with permission from CardioExchange, the cardiology social media website published by the New England Journal of Medicine. Steven Coca is a nephrologist at the Yale School of Medicine. 

Reality Check: The ORIGIN of Spin in a Randomized Trial

by Steven Coca, DO, MS

In the ORIGIN randomized trial, involving about 12,500 people who had diabetes or were at risk for it, insulin glargine showed no advantage over standard care in preventing the primary composite cardiovascular endpoints at a median follow-up of 6.2 years (see news coverage on CardioExchange). ORIGIN was a completely negative trial, yet in the article’s abstract the authors reported a benefit of basal insulin in the secondary endpoint of incident diabetes (odds ratio [OR], 0.80; 95% CI, 0.64–1.00; P=0.05) and stated that the treatment “reduced new-onset diabetes.” The discussion section of the paper further asserted that the treatment “slowed progression of dysglycemia.”

A few qualifications are in order:

1. This seemingly positive finding (in incident diabetes) was for only one of several secondary endpoints, and the alpha level needed to detect a difference was not corrected for multiple outcome assessments.

2. Among the 1456 participants without diabetes at randomization, only 44% of insulin glargine recipients and 47% of standard-care recipients underwent both prespecified oral glucose tolerance tests at the end of the study. So, in effect, fewer than half of the patients were assessed on the one, barely positive endpoint of incident diabetes. Plus, the fact that an absolute 3% more of the control group underwent the necessary testing could have resulted in ascertainment bias.

3. Incident diabetes among those 1456 participants was much greater than 10% (30% in the insulin glargine group, 35% in the standard-care group), but the authors reported an odds ratio rather than a relative risk, yielding an overinflation of the purported benefit  The relative risk would have been 0.86, compared with the reported OR of 0.80. (Only when the probability of a disease is low does the odds ratio approximate the relative risk.)

4. The upper boundary of the confidence interval included 1.00.

Despite these realities, Sanofi and the investigators didn’t hesitate to “spin” the trial findings to the media. The Sanofi press release stated, “…the results also showed that insulin glargine delayed progression from pre-diabetes to type 2 diabetes.” Sanofi’s VP of Medical Affairs said, “ORIGIN shows that it is possible to maintain low and stable HbA1c levels that are close to normal over a long time, and to potentially delay the progression from pre-diabetes to diabetes.” One of the lead investigators took this positive angle: “We know that in this study, insulin lowered blood sugar levels and did so safely and effectively. I can look at a patient and say, ‘Your blood sugar is not well controlled right now, so let’s go ahead and add insulin’.”

There is a temptation for those involved in a trial to present findings as positive, even if the positive aspect is only a morsel. However, scientists should stick to the facts. The first sentence of the abstract of this paper asked whether “the provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events.” The results of the trial tell us that the answer is simply “No.”

How did you read the ORIGIN trial? What’s your take on the facts versus the spin?